Dear Members,
Your directors have pleasure to presenting the 8th (Eighth) Annual Report on the
business and operations of the Company together with the Audited Statement of Accounts for
the financial year ending on March 31, 2024.
FINANCIAL HIGHLIGHTS
The financial performance of the Company for the financial year ending on March 31,
2024 is summarized below:
Particulars |
As on March 31st 2024 |
As on March 31st 2023 |
Paid-up Share Capital |
1,601.62 |
1,284.22 |
Total Revenue |
17331.48 |
12,379.59 |
Total Expenses |
15,390.76 |
11,330.75 |
Depreciation |
100.18 |
53.60 |
Profit before tax |
1,940.72 |
995.24 |
Total Tax Expense |
432.93 |
235.16 |
Profit/(Loss) after taxation |
1,507.79 |
760.08 |
reserves & surplus
During the Financial year company earned net profit of Rs. 1,50,779,000 and the same
has been transferred to the General Reserve of the Company.
dividend
To strength the financial position of the company and to augment working capital, your
director did not declare any dividend including interim dividend.
STATE OF COMPANY'S AFFAIRS AND
future outlook
INDIAN DENTAL CARE INDUSTRY OVERVIEW
India climbed to the 63rd rank among 190 countries in the World Bank's Ease of
Doing Business' rankings in 2020. The World Bank's Logistics Performance Index (LPI) 2023
has ranked India at 38th position (out of 139 economies), recording an improvement of 6
positions. As of 2024, the Indian healthcare sector is one of India's largest employers as
it employs a total of 7.5 million people. Progress in telemedicine, virtual assistants,
and data analytics is expected to create 2.7-3.5 million new tech jobs.
Rising income levels, an ageing population, growing health awareness and a changing
attitude towards preventive healthcare is expected to boost healthcare services demand in
the future. The low cost of medical services has resulted in a rise in the country's
medical tourism, attracting patients from across the world. Moreover, India has emerged as
a hub for R&D activities for international players due to its relatively low cost of
clinical research.
The healthcare sector, as of 2024 is one of India's largest employers, employing a
total of 7.5 million people. The demand for Indian healthcare professionals is expected to
double nationally and globally by 2030 due to a shortage of healthcare workers in India,
where there are only 1.7 nurses per 1,000 people and a doctor-to- patient ratio of 1:1,500
nationwide.
The Indian dental industry consists mainly of independent clinics operated by
individual dentists. However, there has been a recent emergence of dental specialty chains
in major cities of India, which are often supported by venture capital or private equity
funding. These chains have contributed significantly to the growth of the industry by
promoting the use of advanced, high-quality tools, fittings, and equipment. Indian
companies primarily focus on the production of clinical disposables, instruments,
disinfectant tools, sterilizing equipment, impression materials, and temporary materials
for tooth filling.
The high-end segment of the market, such as dental implants, fittings, and prosthetics,
is mainly dominated by foreign players with local presence in India, although many Indian
companies also manufacture under license for foreign manufacturers while simultaneously
engaging in trade and importing activities. Currently, there are around 5,000+ dental
laboratories and 300+ dental institutes providing basic and advanced oral health care. As
the number of dental chains increases, the organized dental clinics' share is expected to
grow across the country. India has 3,00,000+ registered dental graduates, and 280,000+ are
actively practicing dentists. 99% of the dental market in India is private. Over 50% of
dentists work in and around major cities.
operational performance of the company for last three financial years is given below:
Particulars |
FY 2023-24 |
FY 2022-23 |
FY 2021-22 |
Number of Orders |
430574 |
316,795 |
202,335 |
Number of Customer served |
90389 |
73,542 |
61,465 |
Revenue from operations (Rs. In lakhs) |
17,188.31 |
12,326.78 |
7,692.05 |
successful listing on the national stock exchange
The Company's shares were listed on NSE SME exchange on June 02, 2023 at a whopping
premium of 65 per cent against its price band of Rs. 121 to Rs. 128 per equity share. The
Company's stock opened at Rs. 211 per share. The Company pursuant to the Initial Public
Offering offered 42,24,000 Equity Shares of face value of Rs. 10/- each, comprising of
fresh issue of 31,74,000 Equity Shares and Offer for Sale of 10,50,000 for public
subscription.
management discussion and analysis report
The Management Discussion and Analysis Report for the year under review as required
under Regulation 34 of SEBI (Listing Obligations and Disclosure Regulations) Regulations,
2015 is given as a separate statement forming part of the Annual Report.
change in nature of business
During the year under review, there were no changes in nature of business of the
Company.
changes in share capital and listing
During the year under review, there has been no change in the Authorized Share Capital
of the Company.
The Paid-Up Share Capital of the Company as on date is Rs. 16,01,62,080/- (Rupees
Sixteen Crores Sixty-Two Lacs and Eighty Rupees Only) divided into 1,60,16,208 (Rupees One
Crore Sixty Lacs and Sixteen Thousand Two Hundred and Eight only) Equity Shares of Rs.
10/- (Rupees Ten only).
Further, the Company has got listed on NSE SME on June 02, 2023 and offered 42,24,000
Equity Shares of face value of Rs. 10/- each, comprising of fresh issue of 31,74,000
Equity Shares and Offer for Sale of 10,50,000 for public subscription.
The Annual Listing Fees for the year 2024-25 has already been paid.
changes in registered office of the company
During the year under review, there was no change in the Registered Office of the
Company.
The Registered Office of the Company is situated at Khasra No. 714, Village P.O.
Chattarpur, South Delhi- 110074.
material changes affecting the financial position of the company which have occurred
between the end of financial year of the company to which the financial statements relates
and date of this report
During the period under review, no material changes, events & commitments affecting
the financial position of the Company have occurred.
details of significant & material orders passed by the regulators or courts or
tribunal
During the period under review, no order has been passed by the authorities which
impacts the going concern status and company's operations in future.
details of subsidiary, joint venture or associates
During the period under review, the Company acquired 100% shareholding of Waldent
Innovation Private Limited making it the Wholly Owned Subisidiary of the Company. The
Salient features of the financial statement of the Subsidiary & Joint Venture and
Associate Companies in Form AOC-1 has been annexed as Annexure - I'.
details of directors and key managerial personnel
As on March 31, 2024, the Company has Six Directors comprising of two Executive
Directors and Four NonExecutive Directors out of which Three are Independent Directors.
There is also one woman director along with Chief Financial Officer and Whole time Company
Secretary.
Change in Directors /Key Managerial Personnel till the date of this Report:
The details about the changes in Directors or Key Managerial Personnel by way of
Appointment, change in designation, Resignation, Death, Dis-qualification, variation made
or withdrawn etc. are as follows:
S. No. Name |
Designation |
Nature of Change |
With effect from |
1 Mr Sandeep Aggarwal |
Whole Time Director |
Re-appointment |
September 20, 2023 |
2 Ms. Kriti Arora |
Company Secretary |
Resignation |
November 03, 2023 |
3 Mr. Yashank Taneja |
Company Secretary |
Appointment |
November 03, 2023 |
4 Mr Parmeshwar Ravi |
Additional Independent Director |
Appointment |
March 11, 2024 |
5 Mr. Yashank Taneja |
Company Secretary |
Resignation |
June 29, 2024 |
6 Mr. Akhilesh |
Company Secretary |
Appointment |
August 22, 2024 |
woman director
In terms of the proviso of Section 149(1) of the Companies Act, 2013 read with
Companies (Appointment and Qualifications of Directors) Rules, 2014 including any
statutory modification(s) or re-enactment(s) thereof, as applicable for the time being in
force and any other applicable provisions, of any, your Company has complied with the
requirement of having at least one-Woman Director on the Board of the Company i.e., Mrs.
Akanksha Aggarwal (DIN:10056201), appointed as Woman Director effective from March 01,
2023 of the Company.
key managerial personnel
Dr Vikas Agarwal (Chairman & Managing Director), Mr. Sandeep Aggarwal (Whole time
Director and Chief Financial Officer) and Mr. Akhilesh (Company Secretary) are the Key
Managerial Personnel of the Company, in accordance with the provisions of Rule 8 and Rule
8A of Companies (Appointment & Remuneration of Managerial Personnel) Rules 2014 and
Section 203 of the Companies Act, 2013.
director retire by rotation
Pursuant to the provisions of Section 152 of the Companies Act, 2013 and Articles of
the Association of the Company, all directors except Independent Directors shall be liable
to retire by rotation and out of that, one- third of such directors shall retire from the
office every year. The directors who shall retire by rotation at every AGM shall be those
who have been longest in the office since their last appointment.
Further, pursuant to the provisions of Section 149(13) of the Companies Act, 2013, the
retirement of directors by rotation shall not be applicable to the Independent Directors.
Accordingly, Dr Vikas Agarwal (DIN: 10056201), the Managing Director of the Company,
being longest in his office amongst the Directors is liable to retire by rotation this
year. However, being eligible, he has offered his candidature for re-appointment. This
shall not constitute a break in the office of Dr Vikas Agarwal (DIN: 10056201) as the
Managing Director of the Company.
BOARD'S OPINION REGARDING INTEGRITY, EXPERTISE AND EXPERIENCE (INCLUDING THE
PROFICIENCY) OF THE INDEPENDENT DIRECTORS APPOINTED
The Board is of the opinion that the Independent Directors appointed during the year
under review are person(s) of integrity and possess core skills/expertise/competencies
(including the proficiency) as identified by the Board of Directors as required in the
context of Company's business(es) and sector(s) for the Company to function effectively.
board evaluation
As per Section 134 of the Companies Act read with Companies (Accounts) Rules, 2014,
The Board of Directors carried out an annual evaluation of its own performance, Board
Committees, and Individual Directors in accordance with the Act, Listing Regulations, and
Governance Guidelines. The Nomination and Remuneration Committee led an internal
evaluation process to assess the performance of the Board, its committees, and individual
directors. The performance of Individual Directors was reviewed by the Board and the NRC,
with criteria such as preparedness, constructive contributions, and input in meetings.
Non-Independent Directors, the Board as a whole, and the Chairman of the Company were
evaluated at a separate meeting of Independent Directors, with input from Executive and
Non-Executive Directors. The evaluation results were discussed at the Board meeting, where
an action plan was agreed upon.
disclosures related to board, committees and policies
committees of the board
As on March 31, 2024, the Board has following committees which have been constituted to
oversee specific operational areas in compliance with the requirements of the business and
relevant provisions of the applicable laws and status;
Audit Committee
Nomination and Remuneration Committee
Corporate Social Responsibility (CSR) Committee
Stakeholders' Relationship Committee
audit committee
The Audit Committee of your Company comprises of the following Members:
Mr. Varun Chugh, Independent Director (Chairman)
Mr. Ravi Kant Jagetiya, Independent Director (Member)
Dr. Vikas Agarwal, Chairman and Managing Director (Member)
meeting and attendance
6 (Six) committee meeting were held during financial year 2023-24, as against the
statutory requirement of four meetings on the below mentioned dates:
S. No. Date of Meeting |
Attended by |
|
|
%Attendance at Meeting |
|
Mr. Varun Chugh |
Mr. Ravi Kant Jagetiya |
Dr. Vikas Agarwal |
|
1 01-04-2023 |
Yes |
Yes |
Yes |
100 |
2 18-07-2023 |
Yes |
Yes |
Yes |
100 |
3 23-08-2023 |
Yes |
Yes |
Yes |
100 |
4 11-09-2023 |
Yes |
Yes |
Yes |
100 |
5 03-11-2023 |
Yes |
Yes |
Yes |
100 |
6 29-02-2024 |
Yes |
Yes |
Yes |
100 |
nomination and remuneration committee
The Nomination and Remuneration Committee of your Company comprises of the following
Members:
Mr. Varun Chugh, Independent Director (Chairman)
Mr. Ravi Kant Jagetiya, Independent Director (Member)
Dr Akanksha Agarwal, Non- Executive Director (Member)
The Company has devised policy relating to the appointment of directors, payment of
managerial remuneration, director's qualifications and positive attributes of independence
directors and other related matters as provided under the section 178(3) of companies Act,
2013. This Policy is available on the Company's website at
https://www.dentalKart.com/investors-new.
4 (Four) committee meeting were held during financial year 2023-24 on the below
mentioned dates:
S. No. Date of Meeting |
Attended by |
|
|
|
|
Mr. Varun Chugh |
Mr. Ravi Kant Jagetiya |
DrAkanksha Agarwal |
%Attendance at Meeting |
1 18-07-2023 |
Yes |
Yes |
Yes |
100 |
2 23-08-2023 |
Yes |
Yes |
Yes |
100 |
3 03-11-2023 |
Yes |
Yes |
Yes |
100 |
4 11-03-2024 |
Yes |
Yes |
No |
66.67 |
corporate social responsibility committee
The Company has pursuant to the provisions of Section 135 of the Companies Act 2013 and
Schedule VII constituted a Corporate Social Responsibility Committee of the Board of
Directors comprises the following:
Dr Vikas Agarwal, Chairman and Managing Director (Chairman)
Mr. Ravi Kant Jagetiya, Independent Director (Member)
Mr. Sandeep Aggarwal, Whole time Director & CFO (Member)
This Policy is available on the Company's website at
https://www.DentalKart.com/investors-new.
Under Section 135 of the Act, the Company was required to spend Rs. 10,24,000 (2%) of
the average qualifying net profits of the last three financial years on CSR activities on
projects in FY 2023-24. During the year under review, the Company has spent ' Rs.
10,30,000/- on CSR activities.
2 (Two) Committee meetings were held during financial year 2023-24 on the below
mentioned dates:.
S. No. Date of Meeting |
Attended by |
|
|
|
|
Dr Vikas Agarwal |
Mr. Ravi Kant Jagetiya |
Mr. Sandeep Aggarwal |
%Attendance at Meeting |
1 18-07-2023 |
Yes |
Yes |
Yes |
100 |
2 29-02-2024 |
Yes |
Yes |
Yes |
100 |
stakeholders relationship committee
The constituted Stakeholders Relationship Committee comprises the following:
Mr. Varun Chugh, Independent Director (Chairman)
Dr Vikas Agarwal, Chairman and Managing Director (Member)
Mr. Sandeep Aggarwal, Whole time Director & CFO (Member)
1 (One) Committee meeting was held during financial year 2023-24 on the below mentioned
date:
S. No. Date of Meeting |
Attended by |
|
|
|
|
Mr. Varun Chugh |
Dr Vikas Agarwal |
Mr. Sandeep Aggarwal |
%Attendance at Meeting |
1 30-03-2024 |
Yes |
Yes |
Yes |
100 |
number of meetings of the board
During the period under review, 11 (Eleven) meetings of the Board of Directors of the
Company were held on the below mentioned dates:
S. No. |
Date of Meeting |
Board Strength |
No. of Directors Present |
1 |
01-04-2023 |
5 |
5 |
2 |
17-04-2023 |
5 |
5 |
3 |
12-05-2023 |
5 |
5 |
4 |
22-05-2023 |
5 |
5 |
5 |
30-05-2023 |
5 |
5 |
6 |
18-07-2023 |
5 |
5 |
7 |
23-08-2023 |
5 |
5 |
8 |
11-09-2023 |
5 |
5 |
9 |
03-11-2023 |
5 |
5 |
10 |
12-12-2023 |
5 |
3 |
11 |
29-02-2024 |
5 |
4 |
attendance of directors in the meetings
S. No. Name of Director |
|
Board Meeting |
|
|
No. of Meeting liable to attend |
No. of Meeting attended |
% of Meeting attended |
1 Mr. Sandeep Aggarwal |
11 |
11 |
100 |
2 Mr. Vikas Agarwal |
11 |
10 |
90.90 |
3 Mrs. Akanksha Aggarwal |
11 |
09 |
81.81 |
4 Mr. Ravi Jagetiya |
11 |
11 |
100 |
5 Mr. Varun Chugh |
11 |
11 |
100 |
6 Mr. Parmeshwar Ravi* |
NA |
NA |
NA |
*Mr. Parmeshwar Ravi assumed office as an Independent Director of the Company on March
11, 2024.
number of meetings of the members of the company
S. No. Type of Meeting |
Date of Meeting |
Total Members |
Members Present |
1 Annual General Meeting |
20-09-2023 |
992 |
8 |
directors responsibility statement
In accordance with the provisions of Section 134(3)(c) &134(5) of the Companies Act
2013, your directors
confirm that:
In the preparation of the annual accounts for the financial year ending on march
31, 2024, the applicable accounting standards had been followed along with proper
explanation relating to material departures;
The directors had selected such accounting policies and applied them
consistently and made judgments and estimates that are reasonable and prudent so as to
give a true and fair view of the state of affairs of the company as at 31st march, 2024
and of the profit /loss of the company for that period;
The directors had taken proper and sufficient care for the maintenance of
adequate accounting records in accordance with the provisions of the companies act, 2013
for safeguarding the assets of the company and for preventing and detecting fraud and
other irregularities;
The directors had prepared the annual accounts on a going concern basis;
The directors had laid down internal financial controls to be followed by the
company and such internal financial controls are adequate and operating effectively; and
The directors had devised proper systems to ensure compliance with the
provisions of all applicable laws and that such systems were adequate and operating
effectively.
declaration by independent directors and re-appointment of independent directors
All Independent Directors of the Company have given their declarations that they meet
the criteria of
independence as laid down under Section 149(6) of the Companies Act, 2013 and
Regulation 16(1)(b) of the SEBI Listing Regulations.
In the opinion of the Board, the Independent Directors fulfil the criteria of
independence specified in Section 149(6) of the Companies Act, 2013 read with Rule 5 and 6
of Companies (Appointment & Qualification of Directors) Rules, 2014 and Regulation
16(1)(b) of the SEBI Listing Regulations. The Independent Directors have also confirmed
that they have complied with the Company's Code of Business Conduct & Ethics laid down
for the Board of Directors, Senior Management Personnel and other Employees.
statement in respect of adequacy of internal financial control with reference to the
financial statements
The term "internal financial controls" means the policies and procedures
adopted by the company for ensuring the orderly and efficient conduct of its business,
including adherence to company's policies, the safeguarding of its assets, the prevention
and detection of frauds and errors, the accuracy and completeness of the accounting
records, and the timely preparation of reliable financial information.
The directors had devised proper systems to ensure compliance with the provisions of
all applicable laws and that such systems were adequate and operating effectively.
The management has taken all necessary steps to plug the internal control weaknesses.
The management has implemented an effective and meaningful system in place to safeguard
the assets of the company.
corporate governance
As per the Guidelines and directions of the SEBI and Stock Exchange accordingly the
Company has been adhering to the directions and guidelines, as required and if applicable
on the Company size and type as per Regulation 15 of SEBI (Listing Obligations &
Disclosure Requirements) Regulations, 2015, the Corporate Governance is not applicable on
SME Listed Entities.
MANAGING DIRECTOR (MD) AND CHIEF FINANCIAL OFFICER (CFO) CERTIFICATE
In terms of the Listing Regulations, the certificate, as prescribed in Part B of
Schedule II of the said Regulations, has been obtained from the Chief Financial Officer
and Managing Director of the Company, for the financial year 2023-24 with regard to the
financial statements and other matters. The said certificate forms part of this Annual
Report.
RATIO OF REMUNERATION OF EACH DIRECTOR TO THE MEDIAN EMPLOYEE'S REMUNERATION AND
other prescribed details
Section 197 of Companies Act, 2013 deals with the overall maximum managerial
remuneration and managerial Remuneration in case of absence or inadequacy of profits.
According to this section, the total managerial remuneration payable by a public company,
to its directors, including managing director and whole-time director, and its manager in
respect of any financial year shall not exceed the prescribed limit.
The details with respect to the remuneration of directors and employees as required
under Section 197 of the Act and Rule 5(1) of the Companies (Appointment and Remuneration
of Managerial Personnel) Rules, 2014 is annexed as Annexure - II'.
establishment of vigil mechanism
The Company has a Vigil Mechanism/Whistle Blower Policy and has established the
necessary vigil mechanism
for directors and employees in conformation with Section 177(9) of the Act and
Regulation 22 of SEBI Listing Regulations, to report concerns about unethical behaviour.
This Policy is available on the Company's website at
https://www.DentalKart.com/investors-new.
deposits
Section 73-76 of the Companies Act, 2013 deals with acceptance of deposit from members,
directors, director's relatives and public only in case of the eligible companies.
The Company has not accepted any public deposit during the period under review.
PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS UNDER SECTION 186 THE COMPANIES ACT,
2013
During the Financial Year 2023-24, the Company did not enter into any transaction which
falls under the category of section 186 of the Companies Act, 2013 read with rules framed
there under including any statutory modification(s) or re-enactment(s) thereof as
applicable for the time being in force.
particulars of contracts or arrangements with related parties
Pursuant to the provisions of Section 188 of the Companies Act, 2013 read with rules
framed there under including any statutory modification(s) or re-enactment(s) thereof, as
applicable for the time being in force or any other applicable provisions, if any, the
Company has not entered into any transaction with related parties during the period under
review. Thus, disclosure in Form AOC-2 is not required
In the Financial Year 2023-24, the Company has ended its Related party transactions
with Vasa Dental Supplier, The Dentgist Company, Indian Dental Company, being the Sole
proprietorships in the name of Dr Vikas Agarwal, Managing Director of the Company. The
business of these Sole proprietorships has ceased its business operations.
AUDITORS AND AUDITORS' REPORT Statutory Auditors:
M/s. KRA & Co. (FRN: 020266N), Chartered Accountants were appointed as the
Statutory Auditors of the Company w.e.f., September 20, 2023 to conduct the audit for a
period of 5 Years, from the conclusion of 7th Annual General Meeting till the conclusion
of 12th Annual General Meeting in compliance with the applicable provisions of the
Companies Act, 2013 read with rules framed there under including any statutory
modification(s) or re-enactment(s) thereof, as applicable for the time being in force. The
appointment is valid for the FY 2024-25.
Auditors' Report
No qualification has been raised by the Statutory Auditor in the Financial Statements
of Financial Year 2023-24. Further, no fraud has been reported by auditors under
sub-section (12) of section 143 other than those which are reportable to the Central
Government.
cost records and cost audit
In terms of the provisions of Section 148 of the Companies Act, 2013 read with the
rules made there under, the
secretarial audit and secretarial auditors report
According to the provisions of Section 204 of the Act and the Companies (Appointment
and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed M/s
Naresh Verma & Associates, Company Secretaries (FCS No. 5403, Certificate of Practice
No. 4424), to carry out the Secretarial Audit of the Company. The Report of the
Secretarial Auditor for FY 2023-24 is attached herewith as ANNEXURE-M'.
explantion or comments on qualifications, reservations or adverse remarks or
disclaimers made by the auditors and the practicing company secretary in their reports
There are no qualifications, reservations or adverse remarks made by the Auditors in
their reports.
risk management
The Company has adopted risk management policy including identification therein of
elements of risk, if any, which is in the opinion of the Board may threaten the existence
of the company.
Your Company recognizes risk management as an integral component of good corporate
governance.
annual return
The Annual Return of the Company for the year ended March 31, 2024 as required under
Section 92(3) of the Companies Act 2013 read with Section 134(3) of the Companies Act,
2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014 is
available on the Website of the Company at https://www. DentalKart.com/investors-new.
conservation of energy, technology, absorption, foreign exchange earnings and outgo
The details of Energy, Technology, Absorption, Foreign Exchange Earnings and Outgo are
as under: Conservation of Energy:
Steps taken for conservation |
NIL |
Steps taken for utilizing alternate sources of energy |
NIL |
Capital investment on energy conservation equipments |
NIL |
Technology Absorption: |
|
Efforts made for technology absorption |
NIL |
Benefits derived |
NIL |
Expenditure on Research &Development, if any |
NIL |
Details of technology imported, if any |
NIL |
Year of import |
NIL |
Whether imported technology fully absorbed |
NIL |
Areas where absorption of imported technology has not taken place, if any |
NIL |
Foreign Exchange Earnings/ Outgo (in Rs.):
Earnings |
1,07,50,000 |
Outgo |
41,79,15,000 |
compliance with sexual harassment of women at workplace (prevention, prohibition
AND REDRESSAL) ACT, 2013
The Company has complied with provisions relating to the constitution of Internal
Complaints Committee and other applicable provisions under the Sexual Harassment of Women
at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Your director's further
state that during the year under review, there were no cases filed pursuant to the said
Act.
secretarial standards
The Company has complied with the applicable Secretarial Standards prescribed under
Section 118(10) of the Companies Act, 2013 with respect to Meetings of the Board of
Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company
Secretaries of India.
statutory disclosures
None of the Directors of your Company suffers from the disqualification enshrined under
the provisions of section 164, 165, 167 of the Companies Act, 2013. The Directors of the
Company have made necessary disclosures, as required under various provisions of the Act.
The Company has not defaulted in repayment of loans from banks and financial
institutions.
details of application made or proceeding pending under the insolvency and
BANKRUPTCY CODE, 2016
There were no applications made or any proceedings were pending against the Company
under the Insolvency and Bankruptcy Code, 2016 during the financial year under review.
Further, there was no instance of valuation of amount for settlement of loan(s) from
Banks and Financial Institutions during the financial year under review.
depository system
The Company's shares are compulsorily tradable in electronic form. As on date, 100% of
the Company's Paid- up Equity Share Capital are in dematerialized form with both the
Depositories.
The Company has established connectivity with both Depositories viz. National
Securities Depository Limited (NSDL) and Central Depository Services (India) Limited
(CDSL).
The Company has appointed M/s. Mas Services Limited, a Category-I SEBI registered RTA
as its Registrar and
code of conduct for prevention of insider trading
Pursuant to the Regulation 9 of the SEBI (Prohibition of Insider Trading) Regulations,
2015, the Company is having the Code of Conduct to Regulate, Monitor and Report Trading by
Insiders. The said Code is available on the Company's website at the weblink
https://www.dentalkart.com/investors-new.
the details of difference between amount of the valuation done at the time of one time
settlement and the valuation done while taking loan from the banks or financial
institutions along with the reasons thereof
These provisions are not applicable to the Company.
acknowledgement
The Board place on record their appreciations of the whole hearted and sincere
co-operation received by the Company during the year from the employees, customers/
clients, bankers and various Government authorities at all levels.
Your directors also acknowledge gratefully to the shareholders for their support and
confidence reposed on your company.
By and on behalf of Board of Directors |
vasa denticity limited |
Sd/- |
Dr. Vikas Agarwal |
Chairman and Managing Director |
DIN:07487686 |
Date: August 22, 2024 |
Place:- Delhi |